Reviewer’s report

Title: Adverse Infusion Reactions to Rituximab in Systemic Lupus Erythematosus: A Retrospective analysis

Version: 1 Date: 22 Feb 2019

Reviewer: Laura Ross

Reviewer's report:

Thank you for your revisions.

There is a typographical error in line 7, page 7 of the manuscript.

Does the % range quoted in line 18 on page 9 refer to the infusion reaction rate quoted in this paper?

I would consider re-wording the paragraph on page 9 lines 22-27 as the meaning of this paragraph is not entirely clear as currently stated.

Consider listing the abbreviations used in each table below to clarify the meaning of acronyms for the reader.

Thank you for your comment in your response to reviewers, it is worth considering adding in the paragraph you have stated in this letter about the difference in infusion reaction rates quoted in the study between this publication and the previous publication from your centre. It will explain to the reader of the manuscript why the IR rates are very different between publications in a cohort of patients from the same treatment centre.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my
report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.